Uncategorized
The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer
The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined. Read More